公司資料
Viking Therapeutics 股價、新聞與催化劑
- 股票代碼:
- VKTX
- 交易所:
- NASDAQ
- 產業:
- Biopharma
- 所在地:
- United States
股票表現
33.23 USD (-1.95%)
收盤價
最後更新: 2026年8月24日
3.4B USD
市值
股價為何變動
As of Aug 24, 2026, VKTX closed down 1.95% at $33.23. No new same-company headline was identified in the current news window.
公司概覽
Obesity-Focused Metabolic Biotech
Viking Therapeutics is a clinical-stage biotechnology company advancing therapies for obesity and metabolic disease. Its pipeline is led by VK2735 and supported by additional obesity, liver/metabolic, and rare disease programs.
Lead Franchise: VK2735
VK2735 is a wholly owned dual GLP-1/GIP receptor agonist in development for obesity and related metabolic disorders. Viking is developing both subcutaneous and oral formulations, giving the program a differentiated profile across induction, long-term maintenance, and patient preference.
Phase 3 and Oral Development
The subcutaneous formulation is being evaluated in the Phase 3 VANQUISH-1 and VANQUISH-2 obesity trials, both of which are fully enrolled. Viking is also preparing to start Phase 3 trials of oral VK2735 in the fourth quarter of 2026, positioning the oral program as a potential first oral dual GLP-1/GIP agonist.
Broader Metabolic Pipeline
Viking is expanding the obesity franchise with VK3019, an investigational dual amylin and calcitonin receptor agonist now in Phase 1. The company also lists VK2809, an oral thyroid hormone receptor beta agonist for metabolic and liver disease, and VK0214 for X-linked adrenoleukodystrophy.
未來催化劑
- VK2735 maintenance dosing data expected in the third quarter of 2026.
- Phase 3 oral VK2735 trial initiation expected in the fourth quarter of 2026.
- VK3019 Phase 1 single-ascending-dose study readouts when the trial reports.
近期新聞
- 01
- 02
- 03
- 04
- 05
相似股票
商業成熟度、治療領域或催化劑模式相近的同業公司。